XML 47 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
Segment Reporting [Abstract]    
Number of reportable segments | segment 1  
Number of operating segments | segment 1  
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Revenues $ 13,192 $ 9,104
Cost of product sales 0 270
Cost of manufacturing services 5,400 1,846
Research and development 39,698 46,029
Selling, general and administrative 10,718 14,709
Net loss (41,036) (52,190)
Main Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Other segment income, net 1,588 1,560
Lorigerlimab | Main Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Research and development 8,877 9,616
Vobramitanmab duocarmazine | Main Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Research and development 8,267 9,668
MGC026 | Main Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Research and development 5,953 3,956
MGC028 | Main Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Research and development 3,934 6,204
MGC030 | Main Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Research and development 2,506 1,636
Next-generation T-cell engagers | Main Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Research and development 2,273 2,489
MGD024 | Main Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Research and development 2,192 2,786
ADC | Main Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Research and development 1,799 2,962
Margetuximab | Main Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Research and development 319 3,123
Other programs | Main Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Research and development $ 3,578 $ 3,589